3D Medicines Approved to Launch Anti-PD-L1 in China
publication date: Nov 26, 2021
3D Medicines reported that China's NMPA approved the launch of its anti-PD-L1 therapy, the first subcutaneously administered anti-PD-L1 approved anywhere in the world. Envafolimab, a novel single-domain antibody against PD-L1, is approved as a second line therapy for MSI-H/dMMR cancer in patients with advanced solid tumors. Alphamab Oncology originally discovered the drug, and 3D Medicines became its partner, with both companies responsible for clinical development. Tracon Pharma shares US rights to envafolimab with the two China biopharmas while Simcere will commercialize envafolimab in China. More details...
Stock Symbols: (HK: 9966) (NSDQ: TCON)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.